OncoFrontier·Oct 26ESMO 2026: Blood Tests That Track Cancer Response Early, and What They Do Not Yet ProveEarly ctDNA results from ESMO 2026 show a blood test can track response, but it is not yet proven to guide treatment.
OncoFrontier·Oct 26A $192.5 Million Oncology Data Deal Shows What AI Runs On, and What It Does Not ProveTempus, Bristol Myers Squibb, and Pathos AI signed data agreements worth $192.5 million. It is a business deal, not clinical evidence.
OncoFrontier·Oct 22AI Reads DNA-Repair Clues From Ovarian Cancer Slides.A King’s College London model flags HRD in ovarian cancer from routine slides. Promising, but validation and better sensitivity are needed.
OncoFrontier·Oct 21AI Predicts Cancer Survival Risk From a Single Face Photo.A Mass General Brigham model links face photos to cancer survival risk. Experts ask what it sees and whether it adds to clinical judgement.
CancerFax - Advanced Cancer Treatment·Oct 8China’s ADC Moment: What the 2026 Lung Cancer Data Mean for PatientsTwo Chinese-discovered drugs just cut the risk of death in relapsed small cell lung cancer by more than half. Here is what that means, what…
